Edition:
United States

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

4.85USD
20 Apr 2018
Change (% chg)

$-0.05 (-1.02%)
Prev Close
$4.90
Open
$4.85
Day's High
$5.10
Day's Low
$4.82
Volume
45,528
Avg. Vol
62,151
52-wk High
$14.05
52-wk Low
$4.05

Select another date:

Mon, Mar 19 2018

BRIEF-Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​

* KNIGHT THERAPEUTICS - ‍LICENSE AGREEMENT WITH ARDELYX THAT PROVIDES KNIGHT WITH EXCLUSIVE RIGHTS TO COMMERCIALIZE TENAPANOR IN CANADA​

BRIEF-Ardelyx Reports Qtrly Earnings Per Share $0.21

* ARDELYX REPORTS 2017 FINANCIAL RESULTS AND APPOINTS INDUSTRY VETERAN, JAN LUNDBERG, PH.D., TO BOARD OF DIRECTORS

BRIEF-Ardelyx Says Co Had About $134 Million In Cash

* ARDELYX SAYS ON JAN 8, CO HAD ABOUT $134 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 Source text: (http://bit.ly/2AETXHu) Further company coverage:

BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C

* ARDELYX SUCCESSFULLY COMPLETES T3MPO-3 SAFETY EXTENSION STUDY OF TENAPANOR FOR IBS-C

BRIEF-Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China

* Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China

BRIEF-Ardelyx Inc says has decided to discontinue development of RDX7675 for treatment of hyperkalemia​​

* Ardelyx announces updated development path for its cardiorenal pipeline

BRIEF-Ardelyx qtrly ‍net loss per common share $0.44​

* Ardelyx reports third quarter 2017 operating results and clinical progress

BRIEF-Rock Springs Capital Management reports 5.02 pct passive stake in Ardelyx - SEC Filing

* Rock Springs Capital Management LP​ reports 5.02 percent passive stake in Ardelyx Inc as of Oct 23 - SEC filing Source text : (http://bit.ly/2gXpxsM) Further company coverage:

Select another date: